$MBRX
Moleculin Biotech, Inc.

2024 Q4 Form 10-Q Financial Statement

#000143774924034236 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.172M
YoY Change -17.73%
% of Gross Profit
Research & Development $4.932M
YoY Change 50.37%
% of Gross Profit
Depreciation & Amortization $31.00K
YoY Change -3.13%
% of Gross Profit
Operating Expenses $7.135M
YoY Change 19.98%
Operating Profit -$7.135M
YoY Change 19.98%
Interest Expense $102.0K
YoY Change -68.52%
% of Operating Profit
Other Income/Expense, Net $9.000K
YoY Change -30.77%
Pretax Income -$10.59M
YoY Change 88.81%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.59M
YoY Change 88.84%
Net Earnings / Revenue
Basic Earnings Per Share -$2.85
Diluted Earnings Per Share -$2.85
COMMON SHARES
Basic Shares Outstanding 3.002M 2.562M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.405M
YoY Change -61.74%
Cash & Equivalents $9.405M
Short-Term Investments
Other Short-Term Assets $2.201M
YoY Change -27.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.61M
YoY Change -57.95%
LONG-TERM ASSETS
Property, Plant & Equipment $190.0K
YoY Change -15.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.79M
YoY Change -1.11%
TOTAL ASSETS
Total Short-Term Assets $11.61M
Total Long-Term Assets $11.79M
Total Assets $23.39M
YoY Change -40.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.550M
YoY Change 26.99%
Accrued Expenses $3.043M
YoY Change 61.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.593M
YoY Change 43.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $10.32M
YoY Change 1964.4%
Total Long-Term Liabilities $10.32M
YoY Change 1964.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.593M
Total Long-Term Liabilities $10.32M
Total Liabilities $15.92M
YoY Change 262.94%
SHAREHOLDERS EQUITY
Retained Earnings -$151.5M
YoY Change 24.9%
Common Stock $159.0M
YoY Change 1.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.479M
YoY Change
Total Liabilities & Shareholders Equity $23.39M
YoY Change -40.81%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$10.59M
YoY Change 88.84%
Depreciation, Depletion And Amortization $31.00K
YoY Change -3.13%
Cash From Operating Activities -$6.113M
YoY Change -19.03%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.659M
YoY Change
NET CHANGE
Cash From Operating Activities -6.113M
Cash From Investing Activities 0.000
Cash From Financing Activities 4.659M
Net Change In Cash -1.454M
YoY Change -80.79%
FREE CASH FLOW
Cash From Operating Activities -$6.113M
Capital Expenditures $0.00
Free Cash Flow -$6.113M
YoY Change -19.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Moleculin Biotech, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001659617
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3001895
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3001895
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2227516
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2227516
CY2024Q3 mbrx Number Of Core Drug Technologies
NumberOfCoreDrugTechnologies
3 pure
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
12000 usd
us-gaap Sublease Income
SubleaseIncome
37000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37758
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4671997
dei Entity Address Address Line1
EntityAddressAddressLine1
5300 Memorial Drive, Suite 950
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77007
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
300-5160
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MBRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3001895
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9405000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23550000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2201000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2723000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
11606000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
26273000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
190000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
272000 usd
CY2024Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 usd
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
450000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
524000 usd
CY2024Q3 us-gaap Assets
Assets
23394000 usd
CY2023Q4 us-gaap Assets
Assets
38217000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2550000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2498000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3043000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4317000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5593000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6815000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
390000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
474000 usd
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
9932000 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4855000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
15915000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
12144000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
33000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158957000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
157653000 usd
CY2024Q3 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
4000 usd
CY2023Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
-9000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151485000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131604000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7479000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26073000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23394000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38217000 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4932000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3280000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13274000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12855000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2172000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2635000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6629000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7765000 usd
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
31000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
95000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
7135000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5947000 usd
us-gaap Operating Expenses
OperatingExpenses
19998000 usd
us-gaap Operating Expenses
OperatingExpenses
20712000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7135000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5947000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-19998000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-20712000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1728000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1423000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-76000 usd
CY2024Q3 mbrx Warrant Liabilities Transaction Costs
WarrantLiabilitiesTransactionCosts
993000 usd
CY2023Q3 mbrx Warrant Liabilities Transaction Costs
WarrantLiabilitiesTransactionCosts
-0 usd
mbrx Warrant Liabilities Transaction Costs
WarrantLiabilitiesTransactionCosts
993000 usd
mbrx Warrant Liabilities Transaction Costs
WarrantLiabilitiesTransactionCosts
-0 usd
CY2024Q3 mbrx Loss On Issuance Of Warrant Liabilities
LossOnIssuanceOfWarrantLiabilities
-847000 usd
CY2023Q3 mbrx Loss On Issuance Of Warrant Liabilities
LossOnIssuanceOfWarrantLiabilities
0 usd
mbrx Loss On Issuance Of Warrant Liabilities
LossOnIssuanceOfWarrantLiabilities
-847000 usd
mbrx Loss On Issuance Of Warrant Liabilities
LossOnIssuanceOfWarrantLiabilities
0 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000 usd
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
102000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
324000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
503000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1106000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10592000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5609000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19881000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19500000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.85
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.94
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3714278
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1987283
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2910842
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1961327
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10592000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5609000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19881000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19500000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
14000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
13000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10578000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5619000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19868000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19515000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19881000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19500000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
95000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1299000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1505000 usd
mbrx Common Stock Issued For Licence Rights Under License Agreement
CommonStockIssuedForLicenceRightsUnderLicenseAgreement
0 usd
mbrx Common Stock Issued For Licence Rights Under License Agreement
CommonStockIssuedForLicenceRightsUnderLicenseAgreement
772000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1423000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-76000 usd
mbrx Loss On Issuance Of Warrant Liabilities
LossOnIssuanceOfWarrantLiabilities
-847000 usd
mbrx Loss On Issuance Of Warrant Liabilities
LossOnIssuanceOfWarrantLiabilities
-0 usd
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
106000 usd
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
105000 usd
mbrx Transaction Costs Warrant Liabilities
TransactionCostsWarrantLiabilities
-993000 usd
mbrx Transaction Costs Warrant Liabilities
TransactionCostsWarrantLiabilities
-0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-522000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
573000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
52000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-87000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1389000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-932000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18779000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18694000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
26000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
25000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4660000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
211000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4634000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
186000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-15000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14145000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18566000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23550000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43145000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9405000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24579000 usd
mbrx Non Cash Transaction Costs Related To Warrant Liabilities
NonCashTransactionCostsRelatedToWarrantLiabilities
156000 usd
mbrx Non Cash Transaction Costs Related To Warrant Liabilities
NonCashTransactionCostsRelatedToWarrantLiabilities
0 usd
mbrx Offering Costs Incurred Noncash Or Partial Noncash
OfferingCostsIncurredNoncashOrPartialNoncash
42000 usd
mbrx Offering Costs Incurred Noncash Or Partial Noncash
OfferingCostsIncurredNoncashOrPartialNoncash
0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26073000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37000 usd
CY2024Q1 mbrx Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
456000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4970000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
21587000 usd
CY2024Q2 mbrx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
1000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-25000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
453000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4319000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
8000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
17705000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
353000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10592000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
14000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7479000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
52191000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
141000 usd
CY2023Q1 mbrx Stock Issued During Period Value License Rights
StockIssuedDuringPeriodValueLicenseRights
772000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
499000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7915000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
45684000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-21000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
513000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5976000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40268000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-4000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5609000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
35138000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> Nature of Business </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The terms “MBI” or “the Company”, “we”, “our” and “us” are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in <em style="font: inherit;"> July 2015, </em>with clinical programs for hard-to-treat cancers and viruses. The Company has <span style="-sec-ix-hidden:c120171698">three</span> core technologies, each of which have had <em style="font: inherit;">one</em> or more drugs successfully complete a Phase <em style="font: inherit;">1</em> clinical trial, based substantially on discoveries made at and licensed from MD Anderson Cancer Center (MD Anderson) in Houston, Texas. In <em style="font: inherit;"> July 2024 </em>the Company’s lead program Annamycin completed a Phase <em style="font: inherit;">2</em> trial and has held it End-of-Phase <em style="font: inherit;">1/2</em> meeting with the Food and Drug Administration in the US and in <em style="font: inherit;"> August 2024 </em>announced the preparations for a Phase <em style="font: inherit;">3</em> trial. The Company has <em style="font: inherit;">two</em> wholly owned subsidiaries, Moleculin Australia Pty. Ltd., which was set up to perform certain preclinical development and Moleculin Amsterdam B.V., which acts as its legal representative for clinical trials in Europe. The Company utilizes its own internal resources and funds to conduct some of these trials and also has trials being conducted via physician-sponsored trials. The physician-sponsored trials utilize primarily external funds, such as grant funds, which are <em style="font: inherit;">not</em> presented in these financial statements. The Company does <em style="font: inherit;">not</em> have manufacturing facilities, and all manufacturing activities are contracted out to <em style="font: inherit;">third</em> parties. Additionally, the Company does <em style="font: inherit;">not</em> have a sales organization. The Company’s overall strategy is to seek potential outlicensing or outsourcing opportunities with development/commercialization strategic partners who are better suited for the marketing, sales and distribution of its drugs, if approved.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;">2019,</em> the Company sublicensed its technologies to Animal Life Sciences, Inc. (ALI), to enable research and commercialization for non-human use and share development data. As part of this agreement, ALI issued to the Company a 10% equity interest in ALI. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> May 5, 2023, </em>the Company received a letter from the Nasdaq Capital Market (Nasdaq) notifying the Company that for the prior <em style="font: inherit;">30</em> consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule <em style="font: inherit;">5550</em>(a)(<em style="font: inherit;">2</em>) (Bid Price Rule). The deficiency letter did <em style="font: inherit;">not</em> result in the immediate delisting of the Company's common stock from the Nasdaq. In accordance with Nasdaq Listing Rule <em style="font: inherit;">5810</em>(c)(<em style="font: inherit;">3</em>)(A), the Company was provided an initial period of <em style="font: inherit;">180</em> calendar days, until <em style="font: inherit;"> November 1, 2023, </em>to regain compliance with the Bid Price Rule. On <em style="font: inherit;"> November 2, </em><em style="font: inherit;">2023,</em> the Company received a 180-calendar day extension, until <em style="font: inherit;"> April 29, 2024, </em>from the Nasdaq to regain compliance with Bid Price Rule. On <em style="font: inherit;"> March 5, 2024, </em>the Board of Directors approved a reverse <em style="font: inherit;">1</em>-for-15 reverse stock split effective <em style="font: inherit;">11:59</em> P.M. (Eastern time) on <em style="font: inherit;"> March 21, 2024, </em>with trading to commence on a split-adjusted basis on <em style="font: inherit;"> March 22, 2024. </em>On <em style="font: inherit;"> April 8, 2024, </em>the Company received a letter from Nasdaq notifying the Company that it had regained compliance with Bid Price Rule <em style="font: inherit;">5550</em>(a)(<em style="font: inherit;">2</em>) as a result of the closing bid price of the Company's common stock being at $1.00 per share or greater for the <em style="font: inherit;">10</em> consecutive business days from <em style="font: inherit;"> March 22, 2024 </em>through <em style="font: inherit;"> April 5, 2024. </em>Accordingly, the Company is in compliance with the Bid Price Rule and Nasdaq considers the matter closed.</p>
CY2023Q2 mbrx Nasdaq Compliance Minimum Closing Bid Price Per Share
NASDAQComplianceMinimumClosingBidPricePerShare
1
mbrx Nasdaq Compliance Extension Period
NASDAQComplianceExtensionPeriod
P180D
CY2023Q2 mbrx Nasdaq Compliance Minimum Closing Bid Price Per Share
NASDAQComplianceMinimumClosingBidPricePerShare
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b>Use of Estimates -</b> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors <em style="font: inherit;"> may </em>affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often <em style="font: inherit;"> may </em>yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process <em style="font: inherit;"> may </em>result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151500000 usd
CY2024Q3 us-gaap Cash
Cash
9400000 usd
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4800000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1512000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
765000 usd
CY2024Q3 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
894000 usd
CY2023Q4 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2845000 usd
CY2024Q3 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
431000 usd
CY2023Q4 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
547000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
116000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
100000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3043000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4317000 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
6834
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
20485
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
353000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
493000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1299000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1505000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
37000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
34000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
112000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
99000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
7000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
5000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
17000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
19000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
44000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
39000 usd
us-gaap Lease Cost
LeaseCost
129000 usd
us-gaap Lease Cost
LeaseCost
118000 usd
CY2023Q3 mbrx Operating Lease Monthly Rent Payment
OperatingLeaseMonthlyRentPayment
4700 usd
CY2023Q3 mbrx Operating Lease Rent Expense Annual Increase In Rent Percent
OperatingLeaseRentExpenseAnnualIncreaseInRentPercent
0.02 pure
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
12000 usd
us-gaap Sublease Income
SubleaseIncome
37000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
39000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
34000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
107000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
109000 usd
CY2024Q3 mbrx License Agreements Expense
LicenseAgreementsExpense
767000 usd
CY2023Q3 mbrx License Agreements Expense
LicenseAgreementsExpense
221000 usd
mbrx License Agreements Expense
LicenseAgreementsExpense
1300000 usd
mbrx License Agreements Expense
LicenseAgreementsExpense
552000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001437749-24-034236-index-headers.html Edgar Link pending
0001437749-24-034236-index.html Edgar Link pending
0001437749-24-034236.txt Edgar Link pending
0001437749-24-034236-xbrl.zip Edgar Link pending
ex_721362.htm Edgar Link pending
ex_721363.htm Edgar Link pending
ex_721364.htm Edgar Link pending
ex_721365.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mbrx-20240930.xsd Edgar Link pending
mbrx20240930d_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
moleculinnewlogoresized.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
mbrx-20240930_cal.xml Edgar Link unprocessable
mbrx-20240930_def.xml Edgar Link unprocessable
mbrx-20240930_lab.xml Edgar Link unprocessable
mbrx-20240930_pre.xml Edgar Link unprocessable
mbrx20240930d_10q_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending